Psilocybin compositions
Methods and compositions are disclosed for enhancing neurogenesis, resolving neuropathy and improving neurological health and functioning using fungal extracts and their active ingredients, including species of mushrooms and mycelia containing psilocybin and psilocin, combined with erinacines and hericenones or fungal extracts containing those active ingredients, with the addition of nicotinic acid. The compositions may optionally be combined with nervine plants.
1. A pharmaceutical formulation comprising of: 0.1 mg to 10 mg of psilocybin or psilocin; and an extract of Hericium erinaceus comprising 0.1 mg to 200 mg of erinacines or hericenones.
2. The formulation of claim 1 , further comprising 1 mg to 50 mg of niacin.
3. The formulation of claim 1 , further comprising one or more pharmaceutically acceptable excipients selected from acidifying agents, alkalizing agents, buffering agents, antimicrobial preservatives, antioxidants, or tablet disintegrants.
4. The formulation of claim 1 , further comprising extracts of Bacopa monnieri, Centella asiatica, Gingko biloba, Zingiber officinale, Ocimum sanctum, Polygonum cuspid atum, Origanum vulgare, Origanum onites, Rosmarinus officinalis, Rosmarinus eriocalyx, Curcuma longa, Camellia sinensis, Lavandula species, Scutellaria lateriflora, Avena sativa and Avena byzantine, Salvia divinorum, Banisteriopsis caapi, Psychotria species, Tabemanthe iboga, Voacanga africana, Tabemaemontana undulate, Ipomoea tricolor, Argyreia nervosa, Cannabis sativa, Cannabis indica, Cannabis ruderalis , or combinations thereof.
5. The formulation of claim 1 , further comprising one or more of: mycelia, fruitbodies, mycelial extracts, or fruitbody extracts of fungi selected from Antrodia, Beauveria, Copelandia, Cordyceps, Ganoderma, Grifola, Hericium, Inonotus, Isaria, Panaeolus, Phellinus , or combinations thereof.
6. A pharmaceutical formulation comprising of: 0.1 mg to 10 mg of psilocybin or psilocin; an extract of Hericium erinaceus comprising 0.1 mg to 200 mg of erinacines or hericenones; and 1 mg to 50 mg of niacin.
7. The formulation of claim 6 , further comprising one or more pharmaceutically acceptable excipients selected from acidifying agents, alkalizing agents, buffering agents, antimicrobial preservatives, antioxidants, or tablet disintegrants.
8. The formulation of claim 6 , further comprising extracts of Bacopa monnieri, Centella asiatica, Gingko biloba, Zingiber officinale, Ocimum sanctum, Polygonum cuspid atum, Origanum vulgare, Origanum onites, Rosmarinus officinalis, Rosmarinus eriocalyx, Curcuma longa, Camellia sinensis, Lavandula species, Scutellaria lateriflora, Avena sativa and Avena byzantine, Salvia divinorum, Banisteriopsis caapi, Psychotria species, Tabemanthe iboga, Voacanga africana, Tabemaemontana undulate, Ipomoea tricolor, Argyreia nervosa, Cannabis sativa, Cannabis indica, Cannabis ruderalis , or combinations thereof.
9. The formulation of claim 6 , further comprising one or more of: mycelia, fruitbodies, mycelial extracts, or fruitbody extracts of fungi selected from Antrodia, Beauveria, Copelandia, Cordyceps, Ganoderma, Grifola, Hericium, Inonotus, Isaria, Panaeolus, Phellinus , or combinations thereof.
10. A pharmaceutical formulation comprising of: 0.1 mg to 10 mg psilocybin or psilocin; and 1 mg to 50 mg of niacin.
11. The formulation of claim 10 , further comprising an extract of Hericium erinaceus comprising 0.1 mg to 200 mg of erinacines or hericenones.
12. The formulation of claim 10 , further comprising one or more pharmaceutically acceptable excipients selected from acidifying agents, alkalizing agents, buffering agents, antimicrobial preservatives, antioxidants, or tablet disintegrants.
13. The formulation of claim 10 , further comprising extracts of Bacopa monnieri, Centella asiatica, Gingko biloba, Zingiber officinale, Ocimum sanctum, Polygonum cuspid atum, Origanum vulgare, Origanum onites, Rosmarinus officinalis, Rosmarinus eriocalyx, Curcuma longa, Camellia sinensis, Lavandula species, Scutellaria lateriflora, Avena sativa and Avena byzantine, Salvia divinorum, Banisteriopsis caapi, Psychotria species, Tabemanthe iboga, Voacanga africana, Tabemaemontana undulate, Ipomoea tricolor, Argyreia nervosa, Cannabis sativa, Cannabis indica, Cannabis ruderalis , or combinations thereof.
14. The formulation of claim 10 , further comprising one or more of: mycelia, fruitbodies, mycelial extracts, or fruitbody extracts of fungi selected from Antrodia, Beauveria, Copelandia, Cordyceps, Ganoderma, Grifola, Hericium, Inonotus, Isaria, Panaeolus, Phellinus , or combinations thereof.
15. A pharmaceutical dosage comprising a tablet, capsule, elixir, or suspension comprising of: 0.1 mg to 10 mg psilocybin or psilocin; an extract of Hericium erinaceus comprising 0.1 mg to 200 mg of erinacines or hericenones; and 1 mg to 50 mg of niacin.
16. The dosage form of claim 15 , further comprising one or more pharmaceutically acceptable excipients selected from acidifying agents, alkalizing agents, buffering agents, antimicrobial preservatives, antioxidants, or tablet disintegrants.
17. The dosage form of claim 15 , further comprising extracts of Bacopa monnieri, Centella asiatica, Gingko biloba, Zingiber officinale, Ocimum sanctum, Polygonum cuspid atum, Origanum vulgare, Origanum onites, Rosmarinus officinalis, Rosmarinus eriocalyx, Curcuma longa, Camellia sinensis, Lavandula species, Scutellaria lateriflora, Avena sativa and Avena byzantine, Salvia divinorum, Banisteriopsis caapi, Psychotria species, Tabemanthe iboga, Voacanga africana, Tabemaemontana undulate, Ipomoea tricolor, Argyreia nervosa, Cannabis sativa, Cannabis indica, Cannabis ruderalis , or combinations thereof.
18. The dosage form of claim 15 , further comprising one or more of: mycelia, fruitbodies, mycelial extracts, or fruitbody extracts of fungi selected from Antrodia, Beauveria, Copelandia, Cordyceps, Ganoderma, Grifola, Hericium, Inonotus, Isaria, Panaeolus, Phellinus , or combinations thereof.